ADVERTISEMENT

Hospitalists Poised to Prevent, Combat Antibiotic-Resistant Pathogens

The Hospitalist. 2013 November;2013(11):

“If either of those things were to change—for example, if the rate of infections were to increase, or if these isolates were to become more resistant—then we would have to think about changing this from a serious threat to an urgent threat,” Dr. Patel says.

Another infection in the serious category that should be on hospitalists’ radar is drug-resistant Streptococcus pneumoniae. A new vaccine is helping to decrease the number of these infections, but hospitalists should be vigilant about infections that could escape the vaccine and become resistant, Dr. Patel says.

The report estimates as much as $20 billion in excess healthcare costs due to antimicrobial-resistant infections, with $35 billion in lost productivity in 2008 dollars.1

Ketino Kobaidze, MD, assistant professor at the Emory University School of Medicine in Atlanta and a member of the antimicrobial stewardship and infectious disease control committees at Emory University Hospital Midtown, says the sheer numbers are sure to get people to take notice.

“Two million is lots of patients,” she says. “It’s eye-opening, really, for many doctors and patients and society.”

The silver lining, she says, is that the field is moving toward diagnostic tools that will provide quick feedback on the type of infection at work.

It may be that hospitalists have no choice but to give an antibiotic to a patient because of the risk involved in not giving one; however, providers should quickly tailor that treatment to target the specific pathogen when more information is available.

“Two million is lots of patients. It’s eye-opening, really, for many doctors and patients and society.”

—Ketino Kobaidze, MD, assistant professor, Emory University School of Medicine, Atlanta, member, antimicrobial stewardship and infectious disease control committees, Emory University Hospital Midtown

“The most important thing, I think, for hospital medicine and medicine anywhere, is to follow up with whatever you’re ordering and notice right away what happens with these tests. If it’s positive or negative, redirect your care,” Dr. Kobaidze says. “Time is really an important issue here.

“As hospitalists, we need to be extremely cautious not to give them something they don’t need.”

Dr. Kobaidze was particularly struck by gonorrhea being listed in the “urgent” threat category.

“It was so easy to treat before,” she says. “It was nothing, piece of cake. This makes me a little bit concerned.”

Robert Orenstein, DO, an infectious disease expert at Mayo Clinic, praises the report and says hospitalists have a key role to play.

“I think this has a clear impact on hospitalists, who are the primary caregivers of many of these ill patients,” he says. “We need to educate them and build systems that target antimicrobials to the infecting agents and limit their use. Hospitalists are also the people who can help protect patients from the spread of these in the hospital by following appropriate infection prevention guidelines and educating their colleagues of the importance of this.”

He also stresses the importance of being aware of threats within your specific region.

“Many of these MDROs [multi-drug resistant organisms] have regional prevalence,” he says. “And it’s important to know which bugs are in your region so you can work with your institution and public health to tackle these.”


Tom Collins is a freelance writer in South Florida.

Stubborn Bugs

The CDC has created three levels of threats posed by antibiotic-resistant pathogens:

Urgent Threats

  • Clostridium difficile: 14,000 deaths a year; not yet resistant to antibiotics used, but spreads rapidly; stronger strain emerged in 2000.
  • Carbapenem-resistant Enterobacteriaceae (CRE): 600 deaths a year; some resistant to nearly all antibiotics, including carbapenems, considered the antibiotics of last resort.
  • Drug-resistant Neisseria gonorrhoeae: 246,000 drug-resistant infections a year; easily transmitted; showing resistance to the antibiotics used for treatment, including cefixime, ceftriaxone, azithromycin, and tetracycline.

Serious Threats

  • Multidrug-resistant Acinetobacter: 7,300 multidrug-resistant infections a year; about 63% of these bacteria considered multidrug-resistant, meaning at least three different classes of antibiotic no longer cure the infections.
  • Drug-resistant Campylobacter: 310,000 drug-resistant infections a year; showing resistance to ciprofloxacin and azithromycin; these infections sometimes last longer.
  • Fluconazole-resistant Candida (a fungus): 46,000 infections among hospitalized patients per year; showing increasing resistance to first and second line antifungal treatments.
  • Extended spectrum Beta-lactamase-producing Enterobacteriaceae (ESBLs): 26,000 drug-resistant infections a year; some are resistant to nearly all penicillins and cephalosporins, requiring use of last-resort carbapenems, leading to greater resistance to carbapenems.
  • Vancomycin-resistant Enterococccus (VRE): 20,000 drug-resistant infections a year; often cause infections among very sick hospitalized patients; some strains resistant to vancomycin, a last-resort treatment.
  • Multidrug-resistant Pseudomonas aeruginosa: 6,700 multidrug-resistant infections a year; some strains found to be resistant to nearly all, or all, antibiotics.
  • Drug-resistant nontyphoidal Salmonella: 100,000 drug-resistant infections a year; showing resistance to ceftriaxone, ciprofloxacin, and multiple classes of drugs.
  • Drug-resistant Salmonella Typhi: 3,800 drug-resistant infections a year; showing resistance to ceftriaxone, azithromycin, and ciprofloxacin.
  • Drug-resistant Shigella: 27,000 drug-resistant infections a year; high resistance to traditional first-line drugs and now showing resistance to alternatives such as ciprofloxacin and azithromycin.
  • Methicillin-resistant Staphylococcus aureus (MRSA): 80,461 severe infections a year; resistance to methicillin and related antibiotics (nafcillin, oxacillin) and to cephalosporins.
  • Drug-resistant Streptococcus pneumoniae: 1.2 million drug-resistant infections a year; has developed resistance to drugs in the penicillin and erythromycin groups and to less commonly used drugs.
  • Drug-resistant tuberculosis: 1,042 drug-resistant infections a year; resistance to drugs used for standard therapy; some TB is multidrug-resistant and resistant to fluoroquinolone and second line injectables like amikacin, kanamycin, and capreomycin.

Concerning Threats

  • Vancomycin-resistant Staphylococcus aureus (VRSA): 13 cases since 2002; resistance to vancomycin leaves few or no treatment options.
  • Erythromycin-resistant Group A Streptococcus: 1,300 drug-resistant infections a year; resistance to clindamycin and macrolides.
  • Clindamycin-resistant Group B Streptococcus: 7,600 drug-resistant infections a year; has developed resistance to clindamycin, erythromycin, and azithromycin; recently, the first cases of resistance to vancomycin have been detected.